1,089 results on '"Merghoub, Taha"'
Search Results
2. Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
3. Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models
4. TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
5. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
6. Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer
7. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
8. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non–Small Cell Lung Cancer
9. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
10. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
11. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
12. TAD hierarchy restricts poised LTR activation and loss of TAD hierarchy promotes LTR co-option in cancer
13. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
14. Fundamental immune–oncogenicity trade-offs define driver mutation fitness
15. Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients
16. Anatomic position determines oncogenic specificity in melanoma
17. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
18. Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
19. In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response
20. Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases
21. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
22. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
23. Detection and imaging of multiple immunotherapy markers in the tumor microenvironment with SERS nanoprobes for automated treatment response monitoring
24. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
25. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
26. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
27. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
28. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
29. Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model.
30. Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
31. 878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants
32. 968 PD-1hiFoxp3-CD4+tumor-infiltrating T-cell lineage commitment impacts the immunotherapy outcome
33. 525 Investigating dynamic IDO-Kyn-AhR pathway-induced tumor immunosuppression using imaging modality to optimize AhR therapeutic intervention
34. 789 Immune checkpoint blockade augments cyclophosphamide induced anti-tumor immunity by expanding effector CD8+T cell clones in a preclinical melanoma model
35. Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
36. In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology
37. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
38. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
39. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity
40. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
41. Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
42. Polyphenols from Pennisetum glaucum grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells
43. An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models
44. Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness
45. Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
46. Enabling continuous immune cell recirculation on a microfluidic array to study immunotherapeutic interactions in a recapitulated tumour microenvironment.
47. Supplementary Table S5 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
48. Supplementary Methods S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
49. Supplementary Figure S10 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
50. Data from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.